Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

  • Technology appraisal guidance
  • TA298
  • Published: 
  • Last updated: 

History

Review proposal consultation

Choroidal neovascularisation (pathological myopia) - ranibizumab: equality impact assessment - guidance review

Choroidal neovascularisation (pathological myopia) - ranibizumab: final appraisal determination

Choroidal neovascularisation (pathological myopia) - ranibizumab: equality impact assessment - scoping

Choroidal neovascularisation (pathological myopia) - ranibizumab: response to comments on the draft scope and provisional matrix

Choroidal neovascularisation (pathological myopia) - ranibizumab: final matrix

Choroidal neovascularisation (pathological myopia) - ranibizumab: final scope

Choroidal neovascularisation (pathological myopia) - ranibizumab: draft scope - (pre referral)

Choroidal neovascularisation (pathological myopia) - ranibizumab: provisional matrix - (pre referral)